Linda-Gail Bekker

Linda-Gail Bekker is a professor of Medicine, the CEO of the Desmond Tutu Health Foundation, and a former President of the International AIDS Society.

Linda-Gail Bekker
Photo: Fogarty International Center from Bethesda, MD / Wikimedia Commons

Linda-Gail Bekker is a professor of Medicine and the Chief Executive Officer of the Desmond Tutu Health Foundation. She serves as the Director of the Desmond Tutu HIV Centre at the University of Cape Town and was the President of the International AIDS Society from 2016 to 2018.

Born in Zimbabwe, Bekker studied medicine at the University of Cape Town. She initially intended to become a geriatrician but became interested in HIV and TB research after a clinical rotation in KwaZulu-Natal. Her PhD was funded by the John E. Fogarty International Center, and she worked at Rockefeller University on host immunology under doctoral advisor Gilla Kaplan.

In 2009, Bekker won the Royal Society Pfizer Award for her research into tuberculosis epidemiology at the Nyanga Primary Health Clinic in Cape Town. She developed the Tutu tester, a mobile health van that screens for obesity, diabetes, high blood pressure, pregnancy, HIV/AIDS, and TB. She also developed Choices for Adolescent Methods of Prevention in South Africa (CHAMPS) to investigate Pre-exposure prophylaxis and encourage contraception use.

Bekker was elected President of the International AIDS Society in 2016 and gave the opening address at the International AIDS Society Conference in Paris. In 2018, she was elected to the board of the International AIDS Vaccine Initiative. She also serves as an advisor to the President's Emergency Plan for AIDS Relief.

During the COVID-19 pandemic, Bekker was the co-lead investigator of the Sisonke trial alongside Glenda Gray. This phase 3b open label clinical trial ran from 17 February 2021 to 15 May 2021 and administered 478 733 doses of the Jansen (J&J) vaccine to health-care workers in South Africa.

At the 2024 International AIDS Conference in Munich, Professor Bekker presented results from the PURPOSE-1 study. This study showed that twice-yearly injectable lenacapavir fully protects women from HIV infection, with no participants receiving the injection acquiring HIV infection.

Key facts

  • Linda-Gail Bekker was born in Zimbabwe.
  • She served as President of the International AIDS Society from 2016 to 2018.
  • She is the Chief Executive Officer of the Desmond Tutu Health Foundation.
  • She co-led the Sisonke trial for the Jansen (J&J) COVID-19 vaccine.

All sections

Edition